A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

CacoGoblet in literature Milani

Last July an investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. Under the title Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil, the CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).

Organ-on-a-chip, a continuously evolving model

Current models of pre-clinical drug discovery and development, as well as commonly used animal models, are often not suitable for the prediction of human pharmacokinetics (PK). Therefore, one of the biggest challenges today in the field is to find an effective predictive model.

In this way, microphysiological systems (MPS) consisting of multiple linked OoC components are promising tools that provide relevant in vitro to in vivo translation of drug disposition, efficacy and toxicity.

Roche’s study tested mycophenolate mofetil and its metabolites for quantitative evaluation and employed a combination of HT-29 and Caco-2 cells with intestinal-liver OoC.

Histogram reporting the TEER measurements with CacoGoblet in the gut compartment at the start and end of the incubation. The abbreviations L, G, and GL corresponded to the experimental systems of liver-only, gut-only, and gut–liver, respectively. The number is associated with the well of the triplicates measurements of each system. (Lab Chip, 2022,22, 2853-2868 )
Histogram reporting the TEER measurements with CacoGoblet in the gut compartment at the start and end of the incubation. The abbreviations L, G, and GL corresponded to the experimental systems of liver-only, gut-only, and gut–liver, respectively. The number is associated with the well of the triplicates measurements of each system. (Lab Chip, 2022,22, 2853-2868 )

Experimental results

According to the study, the gut-liver OoC system allowed to study the pharmacokinetics of mycophenolate mofetil and its two main metabolites. This opened up the possibility for further research of prodrugs where a combination of intestinal and hepatic processes determine the drug and metabolite exposure.

Furthermore, the team defined a robust and rigorous in silico modelling strategy which was fundamental for the evaluation of the data from the combined gut-liver system.

Finally, the demonstrated ability of the gut-liver OoC to capture the intestinal and liver metabolism of mycophenolate mofetil supports its potential for prediction of pharmacokinetics and drug-drug interaction risk of other orally administered drugs with complex in vivo behavior.

Read full article: Application of a gut–liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil

Communications Department
9 September 2022

Related posts

Caco-2 based in vitro models for the screening of anti-inflammatory drugs

Caco-2 based in vitro models for the screening of anti-inflammatory drugs

Inflammatory reactions of the intestinal tract are the result of a combination of hereditary, genetic and/or environmental factors that have been clustered in the inflammatory bowel disease (IBD). ReadyCell has available CacoReady and CacoGoblet to assay compounds inflammatory properties.

Cancer drug development: what to know about ABC transporters

Cancer drug development: what to know about ABC transporters

The presence of the superfamily members of the ATP binding cassette (ABC) transporters is well established as the main cause of multidrug resistance, since they efflux therapeutic compounds from cells and reduce the intracellular drug levels.